INS and metabolic dysfunction-associated steatohepatitis: Although the antidiabetic drug pioglitazone, which is an insulin-sensitizing agent, has a beneficial effect for NASH, long-term outcomes about its efficacy and safety, including the side effects of cardiovascular disease, congestive heart failure, bladder cancer, and bone loss, have not yet been elucidated [39].